244
Participants
Start Date
July 11, 2021
Primary Completion Date
March 31, 2026
Study Completion Date
March 31, 2026
VIR-2218
VIR-2218 given by subcutaneous injection
VIR-3434
VIR-3434 given by subcutaneous injection
PEG-IFNα
PEG-IFNα given by subcutaneous injection
Investigative Site, Taipei
Investigative Site, Auckland
Investigative Site, Auckland
Investigative Site, Tauranga
Investigative Site, Hamilton
Investigative Site, Wellington
Investigative Site, Baltimore
Investigative Site, Hanover
Investigative Site, Orlando
Investigative Site, Miami
Investigative Site, Taoyuan
Investigative Site, Taichung
Investigative Site, Busan
Investigative Site, Yangsan
Investigative Site, Kuala Lumpur
Investigative Site, Chiayi City
Investigative Site, Frankfurt
Investigative Site, Mannheim
Investigative Site, Kaohsiung City
Investigative Site, Kaohsiung City
Investigative Site, San Francisco
Investigative Site, Hillsborough
Investigative Site, Toronto
Investigative Site, Toronto
Investigative Site, Vancouver
Investigative Site, Hong Kong
Investigative Site, Hong Kong
Investigative Site, Hong Kong
Investigative Site, Chisinau
Investigative Site, Bucharest
Investigative Site, Seoul
Investigative Site, Seoul
Investigative Site, Kyiv
Investigative Site, Birmingham
Investigative Site, London
Investigative Site, London
Investigative Site, Manchester
Vir Biotechnology, Inc.
INDUSTRY